COVID-19, a single-stranded RNA virus, has been a global pandemic for the third year in a row. They can range from asymptomatic or mild flu-like symptoms to severe shortness of breath and death. To date, it is known that it can affect almost every organ in the body, including the cardiovascular, nervous and gastrointestinal systems.
Symptoms in the eyes are not well known, but we would like to inform you through the literature.
Follicular conjunctivitis may develop in the outer eye segment and was said to be the most common ophthalmic symptom in COVID-19 patients. Reports suggest that all symptomatic patients had hyperemia in one or both eyes. Viral keratoconjunctivitis, hemorrhagic and pseudomembranous conjunctivitis, etc. have been reported, and episcleritis has been reported as an early onset of COVID-19.
Invasion of the vitreous and retina at the back of the eye shows various findings, and in fact, central retinal vein occlusion (CRVO), central retinal artery occlusion (CRAO), and acute macular neuroretinopathy ( AMN) have also been reported. It is believed to be a result of a predisposition to arterial and venous thrombosis in patients with novel coronavirus infection. It is said to have occurred within 3 weeks of the onset of symptoms of COVID-19.
As neuroophthalmic findings of COVID-19, papillary phlebitis, cranial nerve palsy, neurogenic ptosis, and cerebrovascular occlusion with vision loss have been reported. Likewise, it can be caused by the procoagulant state of a COVID-19 infection.
Drugs used to treat COVID-19 are also ocularly toxic. The antiviral anti-inflammatory drugs lopinavir, interferon, and tocilizumab have been reported to cause systemic or retinal abnormalities.
Now, social distancing has been lifted and we are in the process of returning to our daily lives. However, if you have a COVID-19 disease or have similar symptoms and have ophthalmic symptoms such as blurred vision, blurred vision, or eye redness, we ask that you visit a hospital for diagnosis and treatment.